^
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    NRG1 overexpression
    Esophageal Squamous Cell Carcinoma
    AV-203
    Sensitive
    :
    C3
    Am J Cancer Res - 3wk
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive
    :
    A1
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    Esophageal Cancer
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    Esophageal Cancer
    nivolumab
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    XP
    Sensitive
    :
    A2
    No biomarker
    Esophageal Adenocarcinoma
    ramucirumab
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    docetaxel + irinotecan
    Sensitive
    :
    A2
    HER-2 positive
    Esophageal Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A2
    HER-2 overexpression
    Esophageal Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    5-fluorouracil + irinotecan
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    irinotecan
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    CaT
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    docetaxel
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    IP
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    cisplatin + paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    cisplatin + 5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    5-fluorouracil + oxaliplatin
    Sensitive
    :
    A2
    No biomarker
    Esophageal Cancer
    capecitabine + oxaliplatin
    Sensitive
    :
    A2
    NTRK3 fusion
    Esophageal Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Esophageal Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    Esophageal Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK3 fusion
    Esophageal Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Esophageal Cancer
    entrectinib
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES